Grant Support for Lynovex

NovaBiotics announces securing innovation grant support from Scottish Enterprise for the company’s inhaled Lynovex programme. The grant is a contribution towards feasibility project costs, and will help accelerate further development of NovaBiotics’ inhaled Lynovex therapy for cystic fibrosis to the next major preclinical milestones. The deliverables of this project will in turn, be key in facilitating entry of inhaled Lynovex into the clinical phase of development. Dr Deborah O’Neil, NovaBiotics CEO commented: “We look forward to this important work getting underway and to expediting the next development milestones for inhaled Lynovex thanks to support from Scottish Enterprise".